CD274 and neoplasm: Codelivery of LY3200882 and programmed cell death protein ligand 1 (PD-L1) siRNA boosts antitumor immunotherapy by downregulating the expression of ECM, promoting the infiltration of effector T cells, resulting in enhanced tumor antigen presentation and reversing the immunosuppressive microenvironment in triple-negative breast cancer [289].